Nature Communications (Feb 2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- Carmen D. Herling,
- Nima Abedpour,
- Jonathan Weiss,
- Anna Schmitt,
- Ron Daniel Jachimowicz,
- Olaf Merkel,
- Maria Cartolano,
- Sebastian Oberbeck,
- Petra Mayer,
- Valeska Berg,
- Daniel Thomalla,
- Nadine Kutsch,
- Marius Stiefelhagen,
- Paula Cramer,
- Clemens-Martin Wendtner,
- Thorsten Persigehl,
- Andreas Saleh,
- Janine Altmüller,
- Peter Nürnberg,
- Christian Pallasch,
- Viktor Achter,
- Ulrich Lang,
- Barbara Eichhorst,
- Roberta Castiglione,
- Stephan C. Schäfer,
- Reinhard Büttner,
- Karl-Anton Kreuzer,
- Hans Christian Reinhardt,
- Michael Hallek,
- Lukas P. Frenzel,
- Martin Peifer
Affiliations
- Carmen D. Herling
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Nima Abedpour
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne
- Jonathan Weiss
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Anna Schmitt
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Ron Daniel Jachimowicz
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Olaf Merkel
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Maria Cartolano
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne
- Sebastian Oberbeck
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Petra Mayer
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Valeska Berg
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Daniel Thomalla
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Nadine Kutsch
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Marius Stiefelhagen
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Paula Cramer
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Clemens-Martin Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing
- Thorsten Persigehl
- Department of Radiology, Cologne University Hospital
- Andreas Saleh
- Department of Diagnostic and Interventional Radiology and Pediatric Radiology, Städtisches Klinikum München Schwabing
- Janine Altmüller
- Center for Molecular Medicine Cologne (CMMC), University of Cologne
- Peter Nürnberg
- Center for Molecular Medicine Cologne (CMMC), University of Cologne
- Christian Pallasch
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Viktor Achter
- Computing Center, University of Cologne
- Ulrich Lang
- Computing Center, University of Cologne
- Barbara Eichhorst
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Roberta Castiglione
- Department of Pathology, University of Cologne
- Stephan C. Schäfer
- Department of Pathology, University of Cologne
- Reinhard Büttner
- Department of Pathology, University of Cologne
- Karl-Anton Kreuzer
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Hans Christian Reinhardt
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Michael Hallek
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Lukas P. Frenzel
- Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University of Cologne
- Martin Peifer
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne
- DOI
- https://doi.org/10.1038/s41467-018-03170-7
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 8
Abstract
BCL2-inhibitor venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (CLL). Here, the authors show the clonal dynamics towards venetoclax resistance by performing whole-exome sequencing of 8 CLL patients undergoing venetoclax treatment.
